Literature DB >> 16809885

Platelet activation in Helicobacter pylori-associated idiopathic thrombocytopenic purpura: eradication reduces platelet activation but seldom improves platelet counts.

Eugene R Ahn1, Maike P Tiede, Wenche Jy, Carlos J Bidot, Vincenzo Fontana, Yeon S Ahn.   

Abstract

INTRODUCTION: It has been suggested that Helicobacter pylori eradication often increases platelet counts in patients with chronic idiopathic thrombocytopenic purpura (ITP). In addition, H. pylori has been shown to induce platelet activation (CD62p or P-selectin expression) in previous studies. We assessed the response of platelet count and CD62p expression after eradication therapy in patients with ITP and H. pylori infection. METHODS AND
RESULTS: We prospectively studied 15 ITP patients diagnosed with H. pylori infection by serology and breath test. A follow-up breath test was used to document eradication. Two out of 15 patients showed improvement in platelet counts after 6 months, 1 of which may have had drug-induced thrombocytopenia. Overall, certain platelet response rate in our series was 6.7% (1/15). We found that platelet CD62p expression by flow cytometry was elevated in 10/15 (66.7%) H. pylori-infected patients, which is a statistically significant difference when compared with 3/33 (9.1%) control ITP patients seronegative for H. pylori (p = 0.002). In addition, eradication therapy decreased CD62p expression (p = 0.04). However, reduction in platelet activation was not associated with an increase in platelet counts (mean 72.4 x 10(9)/l before and 68.7 after therapy; p = 0.4).
CONCLUSION: In our series, platelet activation was common in ITP patients with H. pylori, and eradication therapy decreased platelet activation but seldom increased platelet counts. Increased platelet CD62p expression is a putative link between chronic infections and atherosclerosis, but further study is needed to clarify the implications of our observation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16809885     DOI: 10.1159/000092343

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  16 in total

Review 1.  Helicobacter pylori Eradication in Patients with Immune Thrombocytopenic Purpura: A Review and the Role of Biogeography.

Authors:  Galit H Frydman; Nick Davis; Paul L Beck; James G Fox
Journal:  Helicobacter       Date:  2015-03-01       Impact factor: 5.753

2.  Definition, diagnosis and treatment of immune thrombocytopenic purpura.

Authors:  James N George
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

3.  Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea.

Authors:  Ag Gravina; A Federico; E Ruocco; A Lo Schiavo; M Masarone; C Tuccillo; F Peccerillo; A Miranda; L Romano; C de Sio; I de Sio; M Persico; V Ruocco; G Riegler; C Loguercio; M Romano
Journal:  United European Gastroenterol J       Date:  2015-02       Impact factor: 4.623

4.  Sequential eradication of Helicobacter pylori as a treatment for immune thrombocytopenia in patients with moderate thrombocytopenia: a multicenter prospective randomized phase 3 study.

Authors:  Boram Han; Hyo Jung Kim; Ho-Young Yhim; Doyeun Oh; Sung Hwa Bae; Ho-Jin Shin; Won-Sik Lee; JiHyun Kwon; Jeong-Ok Lee; Hwa Jung Kim; Soo-Mee Bang
Journal:  Ann Hematol       Date:  2022-05-28       Impact factor: 3.673

Review 5.  Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence.

Authors:  Jacek Budzyński; Marek Koziński; Maria Kłopocka; Julia Maria Kubica; Jacek Kubica
Journal:  Clin Res Cardiol       Date:  2014-05-10       Impact factor: 5.460

6.  Long term platelet responses to Helicobacter pylori eradication in Canadian patients with immune thrombocytopenic purpura.

Authors:  Shannon C Jackson; Paul Beck; Andre G Buret; Pamela M O'Connor; Jonathan Meddings; Graham Pineo; Man-Chiu Poon
Journal:  Int J Hematol       Date:  2008-08-01       Impact factor: 2.490

Review 7.  Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms.

Authors:  Masataka Kuwana
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

8.  Helicobacter pylori eradication in patients with chronic immune thrombocytopenic purpura.

Authors:  Ravinder Naik Noonavath; Chandrasekharan Padma Lakshmi; Tarun Kumar Dutta; Vikram Kate
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

9.  Platelet Count Response to Helicobacter pylori Eradication in Iranian Patients with Idiopathic Thrombocytopenic Purpura.

Authors:  Mehrdad Payandeh; Nasrollah Sohrabi; Mohammad Erfan Zare; Atefeh Nasir Kansestani; Amir Hossein Hashemian
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-08-10       Impact factor: 2.576

10.  Effects of Helicobacter pylori eradication in patients with immune thrombocytopenic purpura.

Authors:  Hee Sang Tag; Ho Sup Lee; Su-Hyeon Jung; Bu-Kyung Kim; Sung-Bin Kim; Aeran Lee; Jin Soo Lee; Seong Hoon Shin; Yang Soo Kim
Journal:  Korean J Hematol       Date:  2010-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.